Literature DB >> 16823848

E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain.

G Hossein Ashrafi1, Mohammad Haghshenas, Barbara Marchetti, M Saveria Campo.   

Abstract

Human papillomavirus type 16 E5 protein (HPV-16 E5) is expressed early in papillomavirus infection and is localised primarily in the cell Golgi apparatus (GA) and endoplasmic reticulum. E5 prevents transport of the major histocompatibility class I (MHC I; HLA class I in humans) to the cell surface and retains the complex in the GA. We report that these effects are due, at least in part, to the interaction between E5 and HLA I heavy chain (HC). We also demonstrate that the down-regulation of surface HLA I and interaction with HC are mediated by the first hydrophobic domain of E5. Although E5 downregulates classical HLA selectively as it does not downregulate non-classical HLA, the interaction with the HC of classical HLA I is not specific for a particular haplotype of HLA I. This suggests that E5 can interfere with antigen presentation by most, if not all, classical HLA I haplotypes, with potentially serious consequences as the ability of infected cells to present antigenic peptides to effector T cells would be compromised.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823848     DOI: 10.1002/ijc.22089

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  53 in total

1.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  The canine papillomavirus e5 protein signals from the endoplasmic reticulum.

Authors:  Rachel Condjella; Xuefeng Liu; Frank Suprynowicz; Hang Yuan; Sawali Sudarshan; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

3.  Membrane orientation of the human papillomavirus type 16 E5 oncoprotein.

Authors:  Ewa Krawczyk; Frank A Suprynowicz; Sawali R Sudarshan; Richard Schlegel
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

4.  Tailored immunotherapy for HPV positive head and neck squamous cell cancer.

Authors:  Neil Gildener-Leapman; John Lee; Robert L Ferris
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 5.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

6.  Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry.

Authors:  Ziad Sahab; Sawali R Sudarshan; Xuefeng Liu; YiYu Zhang; Alexander Kirilyuk; Christopher M Kamonjoh; Vera Simic; Yuhai Dai; Stephen W Byers; John Doorbar; Frank A Suprynowicz; Richard Schlegel
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 7.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

8.  Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein.

Authors:  Ewa Krawczyk; John A Hanover; Richard Schlegel; Frank A Suprynowicz
Journal:  Biochem Biophys Res Commun       Date:  2008-05-01       Impact factor: 3.575

Review 9.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  View and review on viral oncology research.

Authors:  Valeria Bergonzini; Cristiano Salata; Arianna Calistri; Cristina Parolin; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2010-05-24       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.